Search for: "Pfizer, Inc." Results 981 - 1000 of 1,512
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 Mar 2010, 12:20 am
In case after case, Tessera Inc. relied on Jianman Qu's expert testimony and computer model to prove patent infringement against the chip industry's biggest companies. [read post]
8 Mar 2010, 5:00 am by Kimberly A. Kralowec
Monier, Inc., ___ Cal.App.4th ___, 2010 WL 630973 (Feb. 24, 2010) Pfizer Inc. v. [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
2 Mar 2010, 3:58 pm by Matt C. Bailey
On March 2, 2010, the Second District (Division 3) published its opinion, issued last week, in Pfizer Inc., v. [read post]
1 Mar 2010, 7:11 pm
Blistex, Ciba, Pfizer, 3M, Edgecraft, Darex, Cisco, Bunn-O-Matic, Oreck, Novartis, Merck, etc. [read post]
1 Mar 2010, 7:11 pm
Blistex, Ciba, Pfizer, 3M, Edgecraft, Darex, Cisco, Bunn-O-Matic, Oreck, Novartis, Merck, etc. [read post]
1 Mar 2010, 12:22 am by Dr. Shezad Malik
A Philadelphia jury yesterday ordered Pfizer Inc.'s Wyeth unit to pay $9.45 million to an Alabama woman who claimed that the company's hormone-replacement drug caused her breast cancer. [read post]
24 Feb 2010, 2:11 am
(Patent Docs) US: PhRMA representative questions follow-on biologics paper (Patent Docs) USPTO announces agenda for next biotechnology/chemical/pharmaceutical customer partnership meeting (Patent Docs)   Products Arzerra (Ofatumumab) – US: Glaxo Group, GlaxoSmithKline seek declaratory judgment of invalidity and non-infringement against Genentech, City of Hope (Patent Docs) Cipro (Ciprofloxacin) – US: Bayer files patent infringement complaints against Lupin in Maryland and Delaware… [read post]
24 Feb 2010, 2:11 am
(Patent Docs) US: PhRMA representative questions follow-on biologics paper (Patent Docs) USPTO announces agenda for next biotechnology/chemical/pharmaceutical customer partnership meeting (Patent Docs)   Products Arzerra (Ofatumumab) – US: Glaxo Group, GlaxoSmithKline seek declaratory judgment of invalidity and non-infringement against Genentech, City of Hope (Patent Docs) Cipro (Ciprofloxacin) – US: Bayer files patent infringement complaints against Lupin in Maryland and Delaware… [read post]
Editor’s Note: John Olson is a founding partner of Gibson, Dunn & Crutcher’s Washington, D.C. office and a visiting professor at the Georgetown Law Center. [read post]
22 Feb 2010, 6:07 am by Beck, et al.
In Goodridge v Pfizer Canada Inc., 2010 ONSC 1095 (Feb. 18, 2010), the plaintiffs claimed injuries from off-label use of Neurontin and its generic version. [read post]
17 Feb 2010, 8:00 am by Karen E. Keller
Your Vitamins Inc. and Andrew Lessman (trademark infringement) 2/9: Pfizer Inc., Pfizer Pharmaceuticals LLC, Pfizer Ireland Pharmaceuticals, Pfizer Limited and CP Pharmaceuticals International CV v. [read post]
16 Feb 2010, 3:45 am by Sean Wajert
Pfizer, Inc., 356 F.3d 1326, 1334 (10th Cir.), cert. denied, 543 U.S. 917 (2004). [read post]
15 Feb 2010, 12:36 pm by Lawrence B. Ebert
Pfizer won as to the Koreman reference:Based on the foregoing, we reverse the rejection of claim 24 under 35 U.S.C. [read post]